Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the coagulation factor deficiency market right now?

In recent years, the coagulation factor deficiency market has seen significant growth. The market, which was worth $4.58 billion in 2024, is predicted to increase to $4.94 billion in 2025, showing a compound annual growth rate (CAGR) of 8.0%. Factors that contributed to this growth throughout the historical period include the rising incidents of hemophilia, the advent of recombinant factors, increased awareness about coagulation disorders, advancements in diagnostic capabilities, governmental assistance for rare diseases, the advent of prophylactic treatments, an enlargement of patient registries, and an escalation in biotechnology investments.

How fast Is the coagulation factor deficiency market expected to grow, and what’s its future value?

The market for coagulation factor deficiency is predicted to see robust growth in the approaching years. It is anticipated to expand to $6.64 billion by 2029 with a compound annual growth rate (CAGR) of 7.7%. This growth during the projected period can be credited to the rising acceptance of gene therapies, surging emphasis on personalized medicine, higher prevalence of coagulation disorders, wider access in emerging markets, and the inclusion of digital health solutions coupled with constant innovation in biomanufacturing technologies. Notable trends in the forecast period encompass gene modification technologies such as CRISPR, evolution of long-acting recombinant factors, progress in gene therapy delivery systems, wearable devices for coagulation monitoring, the use of artificial intelligence for improving treatments, point-of-care diagnostic equipment, drug delivery through nanoparticles, development of plasma-free recombinant products, innovation in biosimilars, and the incorporation of precision medicine methods.

Get your coagulation factor deficiency market report here!

https://www.thebusinessresearchcompany.com/report/coagulation-factor-deficiency-global-market-report

What are the leading drivers of growth in the coagulation factor deficiency market?

The escalating numbers of blood-related maladies are predicted to surge the progress of the coagulation factor deficiency market. These disorders encompass a range of conditions impacting the creation, operation, or makeup of blood cells, platelets, or plasma, and can lead to problems such as anemia, clotting complications, or immune system inadequacies. This upswing can be attributed to key drivers like an ageing demographic, genetic factors, broader awareness, exposure to environmental factors, changes in lifestyle, and the mounting weight of chronic diseases. In addition, advanced diagnostic tools that facilitate early detection are also contributing to this increase. The coagulation factor deficiency plays a crucial role in managing these disorders by supplying imperative clotting factors needed to avert or regulate excessive bleeding, such as in cases of hemophilia where the body’s intrinsic clotting ability is hindered. For example, data from the Leukemia and Lymphoma Society of the US reveals that as of September 2024, a person is diagnosed with leukemia, lymphoma, or myeloma in the US every 3 minutes. This amounted to 187,740 individuals facing these cancers in 2024, making up 9.4% of the projected 2,001,140 new cancer cases in the US. Concurrently, in May 2024, the National Health Service (NHS) England reported that approximately 17,000 individuals in England live with the genetically inherited sickle cell disease, with about 250 new cases recorded each year. The rise in these blood-related disorders is therefore bolstering the growth of the coagulation factor deficiency market.

What are the key segments defining the coagulation factor deficiency market?

The coagulation factor deficiency market covered in this report is segmented –

1) By Product: Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, Biologics, Desmopressin, Other Product Types

2) By Deficiency Type: Haemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, Other Treatment Types

3) By End Users: Hospitals, Clinics, Home Care, Other End Users

Subsegments:

1) By Recombinant Coagulation Factor Concentrates: Recombinant Factor VIII, Recombinant Factor IX, Recombinant Factor VIIa, Other Recombinant Factors

2) By Plasma-derived Coagulation Factor Concentrates: Plasma-derived Factor VIII, Plasma-derived Factor IX, Plasma-derived Factor VII, Other Plasma-derived Factors

3) By Biologics: Monoclonal Antibodies, Gene Therapy Products

4) By Desmopressin: Intravenous Desmopressin, Intranasal Desmopressin

5) By Other Product Types: Fresh Frozen Plasma (FFP), Prothrombin Complex Concentrates (PCC)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21152&type=smp

Who are the key players steering the development of the coagulation factor deficiency market?

Major companies operating in the coagulation factor deficiency market are Pfizer Inc., F Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals, Sanofi Genzyme, Novo Nordisk A/S, Baxter International Inc., CSL Behring LLC, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Swedish Orphan Biovitrum AB, GC Biopharma Co. Ltd., Alnylam Pharmaceuticals Inc., Opko Health Inc., Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., LFB S.A., Biotest AG, Spark Therapeutics Inc., Biogen Inc., Sangamo Therapeutics Inc., Centessa Pharmaceuticals Inc.

What emerging trends are influencing the growth of the coagulation factor deficiency market?

Leading organizations in the coagulation factor deficiency market are emphasizing the importance of creating unique treatments, such as single-use gene therapy. This offers durable or probably curative solutions for individuals suffering from blood clot disorders such as hemophilia, thereby reducing the requirement for constant infusions of coagulation factors. Single-use gene therapy represents a medical procedure that necessitates the addition or modification of genetic material in a patient’s cells to address or possibly cure a disease, with the intention of providing enduring or permanent healing effects after just one application. For instance, Pfizer Inc., a pharmaceutical and biotechnology firm based in the United States, informed in April 2024 that BEQVEZ (fidanacogene elaparvovec-dzkt) has received the approval of the U.S. Food and Drug Administration (FDA) for the treatment of adults experiencing moderate to severe hemophilia B who are presently on factor IX (FIX) preventative therapy. BEQVEZ is a single application adeno-associated virus (AAV)-dependent gene therapy planned to deliver to the transduced cells a functioning copy of the gene that encodes a highly active FIX variant. In the case of patients suffering from hemophilia B, the gene therapy allows them to generate FIX on their own through this single-use treatment, eliminating the need for regular FIX infusions.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21152

Which regions are most influential in expanding the coagulation factor deficiency market?

North America was the largest region in the coagulation factor deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coagulation factor deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Chronic Lower Back Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Lymphocytic Leukemia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lymphocytic-leukemia-treatment-global-market-report

Global Ambulatory IV Infusion Pumps Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/ambulatory-iv-infusion-pumps-global-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: